South Korea · Delayed Price · Currency is KRW Yuyu Pharma Statistics
Total Valuation
Yuyu Pharma has a market cap or net worth of KRW 60.55 billion. The enterprise value is 70.99 billion.
| Market Cap | 60.55B |
| Enterprise Value | 70.99B |
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Yuyu Pharma has 15.75 million shares outstanding. The number of shares has increased by 21.73% in one year.
| Current Share Class | 15.75M |
| Shares Outstanding | 15.75M |
| Shares Change (YoY) | +21.73% |
| Shares Change (QoQ) | -42.46% |
| Owned by Insiders (%) | 35.95% |
| Owned by Institutions (%) | 0.05% |
| Float | 10.09M |
Valuation Ratios
The trailing PE ratio is 7.28.
| PE Ratio | 7.28 |
| Forward PE | n/a |
| PS Ratio | 0.42 |
| PB Ratio | 0.42 |
| P/TBV Ratio | 0.48 |
| P/FCF Ratio | 13.77 |
| P/OCF Ratio | 4.03 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.03, with an EV/FCF ratio of 16.14.
| EV / Earnings | 8.13 |
| EV / Sales | 0.49 |
| EV / EBITDA | 4.03 |
| EV / EBIT | 5.92 |
| EV / FCF | 16.14 |
Financial Position
The company has a current ratio of 1.68, with a Debt / Equity ratio of 0.18.
| Current Ratio | 1.68 |
| Quick Ratio | 0.90 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | 1.54 |
| Debt / FCF | 5.96 |
| Interest Coverage | 5.11 |
Financial Efficiency
Return on equity (ROE) is 6.79% and return on invested capital (ROIC) is 7.86%.
| Return on Equity (ROE) | 6.79% |
| Return on Assets (ROA) | 3.42% |
| Return on Invested Capital (ROIC) | 7.86% |
| Return on Capital Employed (ROCE) | 7.56% |
| Weighted Average Cost of Capital (WACC) | 6.74% |
| Revenue Per Employee | 565.04M |
| Profits Per Employee | 34.36M |
| Employee Count | 254 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.27 |
Taxes
In the past 12 months, Yuyu Pharma has paid 535.53 million in taxes.
| Income Tax | 535.53M |
| Effective Tax Rate | 5.35% |
Stock Price Statistics
The stock price has decreased by -18.51% in the last 52 weeks. The beta is 0.35, so Yuyu Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | -18.51% |
| 50-Day Moving Average | 4,087.30 |
| 200-Day Moving Average | 4,278.85 |
| Relative Strength Index (RSI) | 45.75 |
| Average Volume (20 Days) | 709,300 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Yuyu Pharma had revenue of KRW 143.52 billion and earned 8.73 billion in profits. Earnings per share was 528.40.
| Revenue | 143.52B |
| Gross Profit | 54.44B |
| Operating Income | 11.41B |
| Pretax Income | 10.00B |
| Net Income | 8.73B |
| EBITDA | 17.03B |
| EBIT | 11.41B |
| Earnings Per Share (EPS) | 528.40 |
Balance Sheet
The company has 29.89 billion in cash and 26.21 billion in debt, with a net cash position of 3.67 billion or 233.21 per share.
| Cash & Cash Equivalents | 29.89B |
| Total Debt | 26.21B |
| Net Cash | 3.67B |
| Net Cash Per Share | 233.21 |
| Equity (Book Value) | 142.56B |
| Book Value Per Share | 7,983.19 |
| Working Capital | 38.29B |
Cash Flow
In the last 12 months, operating cash flow was 15.02 billion and capital expenditures -10.63 billion, giving a free cash flow of 4.40 billion.
| Operating Cash Flow | 15.02B |
| Capital Expenditures | -10.63B |
| Depreciation & Amortization | 5.62B |
| Net Borrowing | -15.14B |
| Free Cash Flow | 4.40B |
| FCF Per Share | 279.29 |
Margins
Gross margin is 37.93%, with operating and profit margins of 7.95% and 6.31%.
| Gross Margin | 37.93% |
| Operating Margin | 7.95% |
| Pretax Margin | 6.97% |
| Profit Margin | 6.31% |
| EBITDA Margin | 11.86% |
| EBIT Margin | 7.95% |
| FCF Margin | 3.06% |
Dividends & Yields
This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 2.63%.
| Dividend Per Share | 100.00 |
| Dividend Yield | 2.63% |
| Dividend Growth (YoY) | 15.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 21.31% |
| Buyback Yield | -21.73% |
| Shareholder Yield | -18.98% |
| Earnings Yield | 14.42% |
| FCF Yield | 7.26% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 30, 2021. It was a forward split with a ratio of 2.
| Last Split Date | Mar 30, 2021 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Yuyu Pharma has an Altman Z-Score of 1.98 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.98 |
| Piotroski F-Score | 6 |